Menopause and HRT — structured SAQ (15 marks)

(a) Diagnosis and investigations NOT to order (2 marks)

One mark each. ^[1]

• Diagnosis is clinical in a woman aged 45 or over with characteristic symptoms and amenorrhoea — no blood test is required (NICE NG23).
• Do NOT order FSH, anti-Mullerian hormone, inhibin, oestradiol, antral follicle count or ovarian volume to diagnose menopause in this age group.

(b) HRT regimen, route and progestogen (5 marks)

One mark per point. ^[1][5]

• Combined HRT because she has a uterus — oestrogen plus a progestogen (unopposed oestrogen causes endometrial cancer). Sequential in perimenopause; continuous-combined once postmenopausal.
• Transdermal oestrogen (patch or gel) because her BMI is over 30 and she has a family history of VTE — transdermal does not increase VTE or stroke; oral does.
• Micronised progesterone as the progestogen — VTE-neutral (ESTHER OR 0.7) versus norpregnane derivatives which are thrombogenic (OR 3.9). Endometrium-protective.
• Lowest effective dose of oestrogen, reviewed at 3 months then annually.
• Add vaginal oestrogen separately if systemic HRT does not control her GSM (vaginal dryness).

(c) Risk-benefit using WHI evidence (5 marks)

One mark per point. ^[2][3]

• WHI combined arm (CEE+MPA): CHD 1.29, stroke 1.41, PE 2.13, breast cancer 1.26, hip fracture 0.66 — about 8 more strokes, 8 more PEs and 8 more breast cancers per 10,000 person-years.
• BUT the WHI studied women with a mean age of 63, many a decade past menopause — not this 51-year-old.
• WHI oestrogen-alone arm (hysterectomised): CHD 0.91 (no increase), breast cancer 0.77 (possible reduction), stroke 1.39 — a more favourable profile, and reassurance that oestrogen-only is safer for the breast.
• 18-year mortality follow-up (Manson 2017): all-cause mortality HR 0.99 — HRT does not shorten life; younger women (50-59) tend to benefit.
• For her, in the window of opportunity with transdermal oestrogen and micronised progesterone, the benefit-risk balance is favourable.

(d) Timing hypothesis (3 marks)

One mark per point. ^[4]

• The timing hypothesis (ELITE trial): oral estradiol slowed carotid intima-media thickness progression when started within 6 years of menopause (0.0044 vs 0.0078 mm/year, P = 0.008), but had no effect when started 10 or more years after menopause.
• This is the window of opportunity — oestrogen protects the vasculature when started close to menopause but not a decade later.
• She is 51, recently menopausal, well within the window — this is exactly the population that benefits and is not the WHI late-started population.